占主导地位的右叶缩:基于粉样蛋白状况的临床,神经心理和结构差异
Jacopo Di Napoli1, Andrea Arighi2, Giorgio Conte3
1Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy.
European journal of neurology
|November 7, 2023
概括
显著的右缩可以表明阿尔茨海默氏症或前性痴呆症. 粉样蛋白生物标志物状态在这种缩模式的患者中区分临床和放射学特征.
科学领域:
- 神经学 神经学
- 放射学 放射学是一门学科.
- 神经成像是一种神经成像.
背景情况:
- 占主导地位的右缩是一个放射学标志,通常与前性痴呆有关,但也在阿尔茨海默氏症中观察到.
- 这些疾病之间的临床重叠需要确定区分特征.
研究的目的:
- 根据粉样蛋白生物标志物状态,比较患有突出右前性缩的受试者的临床,神经心理学和MRI数据.
主要方法:
- 从痴呆症中心队列中识别了3级或4级右前缩症的受试者.
- 包括有MRI扫描和粉样蛋白状况的受试者.
- 提取了临床,神经心理学数据,并使用了视觉评级尺度来评估缩和白质超强度.
主要成果:
- 17名受试者符合标准 (7名粉素阳性,10名粉素阴性).
- 粉样蛋白阳性患者最初表现出更多的执行功能障碍和地形失调.
- 粉胺阴性患者在随访时表现出更多的行为症状;粉胺阳性患者的整体神经心理表现更差.
结论:
- 粉样蛋白生物标志物状态对于区分临床,神经心理学和放射学表现在患有主要右缩症的患者中至关重要.
相关概念视频
01:26Alzheimer's Disease: Overview
498
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
498
03:03Amyloid Fibrils
5.3K
5.3K
01:22Alzheimer's Disease: Treatment
197
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
197